XML 41 R24.htm IDEA: XBRL DOCUMENT v3.26.1
LICENSING AGREEMENTS (Details Narrative) - USD ($)
 1 Months Ended 12 Months Ended
Feb. 28, 2022
Dec. 28, 2020
May 17, 2017
Dec. 31, 2025
Dec. 31, 2024
Aug. 31, 2023
Sep. 30, 2021
Jan. 31, 2021
Dec. 31, 2020
Dec. 12, 2020
Feb. 02, 2016
Number of shares                     43,112
Additional CMH payment       $ 50,000              
Obligation due under agreement through the issuance of common stocks       300,000              
Payment for clinical trial       200,000              
Common stock value       3,144 $ 1,749           $ 100,000
Patents gross       $ 300,000              
Total obligation under the agreement             $ 300,000   $ 100,000 $ 300,000  
Initial payment of obligation             $ 40,000   $ 50,000 $ 50,000  
Balance of obligation, description       The remaining portion of the $300,000 obligation was paid in cash in 2020              
Remaining portion of obligation           $ 100,000          
Amortization       $ 123,327 110,452            
Amortization expenses       $ 46,523 $ 45,940            
Common stock shares       3,701,668 1,748,428            
Description of payment on conversion basis     Payment may be made in cash or shares of our common at a discount of 30% to the lowest closing price within 20 business days prior to the conversion date                
Description for the consecutive trading days     In the event the Company’s shares of common stock trade below $0.01 per share for two or more consecutive trading days, the number of any shares issuable as payment doubles.                
Payments upon completion of the IRB clinical trial     $ 200,000                
Payments in the event of commercialization of technology       $ 300,000              
Licensing Agreements [Member]                      
Amortization       0              
Payments upon dosing of the first patient in Phase 3 clinical trial       100,000              
License Agreement [Member]                      
Amortization expenses       861 $ 1,172            
Carrying value of patent       0              
Jadi Cell [Member]                      
Pyment for license fees $ 250,000 $ 250,000                  
Common stock shares 18,018                    
StemSpine LLC [Member]                      
Amortization       10,861 10,000            
Carrying value of patent       $ 14,139              
Expiration period of finite-lived intangible assets       May 19, 2027              
Amortization       $ 10,000              
Option Warrant [Member]                      
Amortization       25,075 25,000            
Carrying value of patent       124,925              
Amortization       25,000              
Initial payment     100,000                
Payments upon dosing of the first patient in Phase 3 clinical trial     400,000 100,000              
Payments upon dosing of the first patient first patient in a Phase 1-2 clinical trial     $ 200,000                
ImmCelz Patent [Member]                      
Patents gross       $ 200,000              
Common stock, shares             8,466 8,929   667  
Discount rate       25.00%              
Amortization expenses       $ 19,989 5,038            
Interest rate       5.00%              
Carrying value of patent       $ 171,659              
Exercise price       $ 0.00              
Amortization       $ 20,000              
EDI Patent [Member]                      
Amortization       9,972 9,972            
Carrying value of patent       1,042              
Amortization       1,042              
IND [Member]                      
Patents gross       100,000              
Amortization       9,989 $ 10,016            
Carrying value of patent       77,495              
Amortization       10,000              
Patents [Member]                      
Carrying value of patent       17,971              
Amortization       $ 17,971